The estimated Net Worth of Aiman Abdel Malek is at least $12.1 Million dollars as of 12 March 2019. Aiman Malek owns over 27,349 units of Insulet stock worth over $11,691,886 and over the last 9 years Aiman sold PODD stock worth over $371,989.
Aiman has made over 9 trades of the Insulet stock since 2018, according to the Form 4 filled with the SEC. Most recently Aiman exercised 27,349 units of PODD stock worth $1,014,374 on 12 March 2019.
The largest trade Aiman's ever made was exercising 27,349 units of Insulet stock on 12 March 2019 worth over $1,014,374. On average, Aiman trades about 1,988 units every 19 days since 2016. As of 12 March 2019 Aiman still owns at least 51,341 units of Insulet stock.
You can see the complete history of Aiman Malek stock trades at the bottom of the page.
Aiman's mailing address filed with the SEC is C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA, MA, 01821.
Over the last 17 years, insiders at Insulet have traded over $64,849,299 worth of Insulet stock and bought 175,262 units worth $7,280,516 . The most active insiders traders include Jonathan Silverstein, Elizabeth H Weatherman, and Samuel D Colella. On average, Insulet executives and independent directors trade stock every 19 days with the average trade being worth of $2,473,148. The most recent stock trade was executed by Timothy J Scannell on 10 September 2024, trading 5,000 units of PODD stock currently worth $1,129,200.
insulet corporation is an innovative medical device company based in billerica, massachusetts. it was founded in 2000 with the mission of improving the lives of people with diabetes. specifically, through its revolutionary omnipod insulin management system, insulet seeks to expand the use of insulin pump therapy. studies have demonstrated the advantages of insulin pump therapy over multiple daily insulin injections (mdi); these advantages include better glycemic control, fewer hypoglycemic events, reduced glycemic variability1 and improved quality of life2. despite these benefits, most people still choose mdi therapy largely due to the complexity, cost and inconvenience of conventional pump technology. the omnipod is a discreet and easy-to-use system that eliminates many of the issues associated with conventional pumps. improvements include omnipod's lack of tubing; automated, virtually pain-free insertion; and two straightforward parts that communicate wirelessly. by breaking down
Insulet executives and other stock owners filed with the SEC include: